Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has announced that in a preclinical study of its influenza DNA vaccine against the virulent, newly emergent H7N9 flu virus, 100% of the vaccinated animals were protected against sickness and death when they were challenged with a lethal dose of H7N9 virus...
More...
More...